NCT04577014 2026-04-14
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Recruiting
Clinical Trials
14 trialsNCT06498648 2026-04-13
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 1/2 Recruiting
NCT04383119 2026-03-25
ISG-ARTICLE
Italian Sarcoma Group
Phase 2 Recruiting
NCT07144254 2026-03-02
Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma
Emory University
Phase 1 Recruiting
NCT06308419 2026-02-25
A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT07359053 2026-01-22
MAGNATE-S
Shanghai 6th People's Hospital
Phase 2 Recruiting
NCT03093909 2025-11-10
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT04807816 2025-10-02
TARSARC
Institut Bergonié
Phase 2 Recruiting
NCT06114004 2025-06-25
SeliSarc
Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas
Phase 2 Recruiting
NCT04535271 2025-02-24
TAGGED
Sarcoma Oncology Research Center, LLC
Phase 2 Recruiting
NCT04999761 2024-09-25
AB122 Platform Study
Taiho Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT04535713 2024-07-05
GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma
Sarcoma Oncology Research Center, LLC
Phase 2 Recruiting
NCT04595994 2024-01-23
SeliSarc
Grupo Espanol de Investigacion en Sarcomas
Phase 1 Recruiting
NCT06114225 2023-11-02
PROMIS
Ruijin Hospital
Phase 2 Recruiting